Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALXN1850 versus placebo in adolescents and adults with hypophosphatasia
ChiCTR2400082318Phase 3Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypophosphatasia (HPP) comparing ALXN1850 with Placebo (2 arms). Primary endpoint: 6-Minute Walk Test. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on ChiCTR2400082318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082318.